<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mast cells: Surface receptors and signal transduction</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mast cells: Surface receptors and signal transduction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mast cells: Surface receptors and signal transduction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mariana C Castells, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lora Bankova, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarbjit Saini, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mast cells display a host of stimulatory and inhibitory surface receptors, allowing them to respond to a variety of stimuli in a modulated manner. The ultimate response of a cell to its environment is determined by the balance of stimulatory and inhibitory factors present at a given moment and acting on different receptors.</p><p>This topic review will discuss the activating and inhibitory receptors on mast cells and signal transduction mechanisms. The information in this review pertains to human mast cells whenever possible, and notation is made when data are derived purely from murine studies. Mast cell-derived mediators, as well as the development, identification, and physiologic roles of mast cells, are reviewed separately. (See  <a class="medical medical_review" href="/d/html/3972.html" rel="external">"Mast cell-derived mediators"</a> and  <a class="medical medical_review" href="/d/html/3979.html" rel="external">"Mast cells: Development, identification, and physiologic roles"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ACTIVATING RECEPTORS</span><span class="headingEndMark"> — </span>Important stimulatory receptors on the surface of mast cells include the high-affinity immunoglobulin E (IgE) receptor, immunoglobulin G (IgG) receptors, Toll-like receptors (TLRs), receptors for stem cell factor (SCF), complement proteins, cytokine receptors (eg, for the alarmins interleukin [IL] 33 and thymic stromal lymphopoietin [TSLP]), neuropeptides, and opioids. A G-coupled protein receptor that is important in non-IgE anaphylactic reactions, MRGPRX2, was identified in 2015 [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h2">High-affinity IgE receptor</span><span class="headingEndMark"> — </span>Classical mast cell activation occurs through the high-affinity IgE receptor, Fc-epsilon-RI. Activation occurs when adjacent receptors, occupied by receptor-bound IgE, are crosslinked by a multivalent antigen. This is a strong stimulus for degranulation and release of preformed mediators, as well as for de novo production and subsequent release of leukotrienes, prostaglandins, and cytokines, including numerous chemokines. (See  <a class="medical medical_review" href="/d/html/3972.html" rel="external">"Mast cell-derived mediators"</a>.)</p><p>High- and low-valency or affinity antigens are able to trigger differential responses through Fc-epsilon-RI receptors. High-affinity or high-valency antigens trigger classic degranulation and cytokine responses with neutrophilic inflammation. In contrast, low-valency or low-affinity allergens may not trigger degranulation but can still trigger production of chemokines that recruit macrophages and monocytes [<a href="#rid2">2,3</a>].</p><p>IgE is involved in defense against parasitic infection and in hypersensitivity reactions. It is estimated that there are usually &gt;100,000 Fc-epsilon-RI receptors on the surface of each human mast cell, although the number can vary with activation state and the presence of circulating IgE [<a href="#rid4">4-6</a>]. As the transcript is stabilized by binding of monomeric IgE to the receptor, there is a greater number of receptors and hence capacity for binding serum IgE in atopic individuals. This likely accounts for this large range in the number of receptors per cell and the efficacy of therapy directed to reducing the serum titer of IgE [<a href="#rid7">7-9</a>]. (See <a class="local">'Clinical applications'</a> below.)</p><p>The fully functional form of the Fc-epsilon-RI receptor on mast cells and on basophils is a tetrameric structure consisting of one alpha chain, one beta chain, and two gamma chains [<a href="#rid10">10,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The alpha chain contains two extracellular domains that bind IgE with high affinity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The beta chain transverses the membrane four times and may form an ion pore.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The two gamma chains, which are structurally homologous to the zeta chain of the T cell receptor, each have two cytoplasmic <strong>i</strong>mmunoreceptor <strong>t</strong>yrosine <strong>a</strong>ctivation <strong>m</strong>otifs (ITAMs) and mediate signal transduction.</p><p></p><p>Several other human cell types express a trimeric form of Fc-epsilon-RI, which lacks the beta chain. This is found on eosinophils, epithelial cells, and antigen-presenting cells, such as dendritic cells, Langerhans cells, and monocytes, and may be involved in the immune modulatory functions of these cells [<a href="#rid10">10,12-16</a>]. (See  <a class="medical medical_review" href="/d/html/3979.html" rel="external">"Mast cells: Development, identification, and physiologic roles", section on 'Acquired immunity'</a>.)</p><p class="headingAnchor" id="H3822991774"><span class="h2">MRGPRX2</span><span class="headingEndMark"> — </span>A Mas-related G protein–coupled receptor, first described in 2015, may be responsible for reactions to quinolone medications, such as <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="16808" href="/d/drug information/16808.html" rel="external">icatibant</a>, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, and general anesthetics, such as <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">atracurium</a>, and others with the central tetrahydroisoquinoline (THIQ) motif [<a href="#rid1">1</a>]. While low concentrations of medications are sufficient to activate mast cells through the IgE receptor, much higher concentrations are needed for MRGPRX2 activation (EC50 varying from 22 to 260 mcg/mL) [<a href="#rid17">17</a>]. Therefore, the plasma concentrations reached by many drugs that are ligands for MRGPRX2 might not be high enough to activate this receptor. Importantly, skin testing concentrations used for most medication skin tests would be too low to activate MRGPRX2 [<a href="#rid17">17</a>]. The extent of the expression of this receptor on human mast cells is not fully understood, although it could potentially explain anaphylactic reactions to these medications in which IgE antibodies have not been demonstrated.</p><p>MRGPRX2 is also expressed on human basophils and eosinophils [<a href="#rid18">18</a>].</p><p>Studies in mice point to a role of the mouse ortholog of MRGPRX2 (Mrgprb2) in nonhistaminergic itch and in mast cell–sensory neuron interactions [<a href="#rid19">19,20</a>]. Whether MRGPRX2 mediates similar reactions in humans has not been established. However, a significant increase in number and percentage (45 versus 22 percent) of MRGPRX2 mast cells has been described in the skin of patients with chronic urticaria compared with that of nonatopic control subjects [<a href="#rid21">21</a>]. In addition, cutaneous mast cells of patients with chronic urticaria show increased reactivity to MRGPRX2 ligands [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H2324383010"><span class="h2">Receptors for mechanical stimulation</span><span class="headingEndMark"> — </span>Mast cell degranulation in response to mechanical stimulation was linked to signaling through the dermatan sulfate adhesion GPCR, ADGRE2. Mutations of ADGRE2 that render it "hyperactive" are associated with a vibratory urticaria phenotype [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/d/html/8109.html" rel="external">"Physical (inducible) forms of urticaria", section on 'Vibratory angioedema and urticaria'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">IgG receptors</span><span class="headingEndMark"> — </span>Human mast cells also express receptors for IgG, including Fc-gamma-RII-alpha and Fc-gamma-RIII, activating receptors that bind IgG3 most avidly [<a href="#rid25">25,26</a>]. These receptors allow activation of the cells by immune complexes that are either circulating or formed in situ. Human mast cells can also transiently express Fc-gamma-RI, another activating receptor [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Kit (stem cell factor receptor)</span><span class="headingEndMark"> — </span>Mast cells express Kit, the receptor for SCF, which is the critical growth factor for mast cell development. (See  <a class="medical medical_review" href="/d/html/3979.html" rel="external">"Mast cells: Development, identification, and physiologic roles", section on 'Kit and stem cell factor'</a>.)</p><p>For mature mast cells, SCF also serves as a chemotactic factor and can be a direct activator, causing degranulation and cysteinyl leukotriene production, and, in conjunction with IL-10 and IL-1-beta, can be an inducer of prostanoid and cytokine production [<a href="#rid28">28-34</a>].</p><p class="headingAnchor" id="H3221240020"><span class="h2">Alarmin receptors</span><span class="headingEndMark"> — </span>Mast cells express the IL-33 receptor known as ST2, which is a member of the IL-1 receptor family as well as a receptor for the alarmin TSLP [<a href="#rid35">35</a>]. Both of these can be released from activated epithelium. The epithelium releases an alternatively spliced form of IL-33, which, in combination with TSLP, activates mast cells. This pathway is likely important in various responses occurring at environmental interfaces. For instance, together with basophils, this pathway for mast cell activation has been implicated in driving the type 2 inflammation in some patients with asthma [<a href="#rid36">36</a>] and in patients with aspirin-exacerbated respiratory disease [<a href="#rid37">37,38</a>]. TSLP-mediated activation of mast cells triggers prostaglandin D2 (PGD2) production and likely contributes significantly to the non-IgE-mediated aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Complement receptors</span><span class="headingEndMark"> — </span>Mast cells in human skin express receptors for both the anaphylatoxins, C3a and C5a, and release histamine in response to exposure to these complement fragments. These provide additional mechanisms in which immune complexes or microbes may activate mast cells that may occur via classical or alternative complement activation pathways. However, in contrast to activation through Fc-epsilon-RI, exocytosis by complement fragments is not associated with the generation of prostaglandins or leukotrienes. There is some variability in distribution of complement receptors as some cardiac mast cells demonstrate a functional receptor for C5a (CD88) by immunofluorescence, whereas mast cells isolated from the human lung, uterus, or tonsils do not [<a href="#rid40">40-43</a>]. (See  <a class="medical medical_review" href="/d/html/3968.html" rel="external">"Complement pathways", section on 'Classical pathway'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Toll-like receptors</span><span class="headingEndMark"> — </span>Mast cells express a variety of TLRs, which are both surface and internal membrane-associated molecules in eukaryotic cells that detect and respond to microbial infection. The activation of mast cells through TLRs is an important mechanism through which mast cells serve as a bridge between the innate and adaptive immune systems. Using cultured human mast cell lines, these cells have been shown to express TLRs 1 through 9, although TLR8 was lost with continued culture [<a href="#rid44">44-46</a>].</p><p>Human mast cells also can be activated by many of the ligands specific to the different receptors (eg, peptidoglycans through TLR2, double-stranded ribonucleic acid [RNA] through TLR3, and lipopolysaccharide [LPS] through TLR4). In broad terms, mast cells respond to activation through TLR with the production of inflammatory cytokines, rather than degranulation, yet the responses to the different stimuli are distinct. Thus, double-stranded RNA induces expression of the type 1 interferons, but not tumor necrosis factor (TNF) alpha or IL-6, while LPS induces expression of these two proinflammatory cytokines, but not degranulation as occurs following peptidoglycan stimulation [<a href="#rid47">47,48</a>]. A general discussion of TLRs is found elsewhere. (See  <a class="medical medical_review" href="/d/html/3985.html" rel="external">"Toll-like receptors: Roles in disease and therapy"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Receptors for neuropeptides and opioids</span><span class="headingEndMark"> — </span>Neuropeptides, such as vasoactive intestinal polypeptide (VIP), substance P, and somatostatin, mediate secretory granule exocytosis from mast cells with little generation of lipid mediators [<a href="#rid49">49-51</a>]. The responses to these neuropeptides are mediated through pertussis-sensitive G proteins, with concomitant release of calcium from intracellular stores [<a href="#rid52">52-54</a>]. Mast cell activation by substance P is at least partially mediated through MRGPX2 [<a href="#rid55">55</a>].</p><p>Certain muscle relaxants, such as <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>, tubocurarine, and <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">atracurium</a>, cause both skin and lung mast cells to release histamine, while opiates also cause histamine release from skin mast cells [<a href="#rid56">56-58</a>]. The latter underlies the common occurrence of pruritus and urticaria in response to opioid analgesics.</p><p class="headingAnchor" id="H9"><span class="h2">Platelet-activating factor receptor</span><span class="headingEndMark"> — </span>Receptors for platelet-activating factor (PAF) have been identified on human mast cells cultured from the lung and from progenitors in peripheral blood [<a href="#rid59">59</a>]. PAF is known to be important in murine anaphylaxis, and preliminary data suggest that PAF plays a role in human anaphylaxis as well, particularly in amplification of the initial response. (See  <a class="medical medical_review" href="/d/html/386.html" rel="external">"Pathophysiology of anaphylaxis", section on 'Chemical mediators of anaphylaxis'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">INHIBITORY RECEPTORS</span><span class="headingEndMark"> — </span>Mast cells express several inhibitory receptors. While the functions of these are not fully understood, some have been shown to regulate mast cell-mediated events including human mast cell activation, and, in the mouse, mast cell-dependent inflammation [<a href="#rid60">60,61</a>]. Many of the inhibitory receptors contain <strong>i</strong>mmunoregulatory <strong>t</strong>yrosine <strong>i</strong>nhibition <strong>m</strong>otifs (ITIMs).</p><p>Examples of ITIM-associated receptors capable of suppressing mast cell activation are Fc-gamma-RIIb, CD300a, platelet-endothelial cell adhesion molecule 1 (PECAM-1), paired immunoglobulin-like receptor B (PIR-B), the c-lectin mast cell function-associated antigen (MAFA), sialic acid-binding immunoglobulin-like lectins (Siglecs), and leukocyte immunoglobulin-like receptor 4, subfamily B, member 4 (LILRB4) [<a href="#rid61">61,62</a>]. PIR-B is a surface receptor expressed on both mast cells and macrophages and appears to regulate basal activation of both cells. Examples of ITIM-independent inhibitory receptors include the mast cell receptor for the glycoprotein CD200, the A2b adenosine receptor, and the transient receptor potential cation channel, subfamily M, member 4 (TRPM4) ion channel [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H2685464576"><span class="h2">Siglecs</span><span class="headingEndMark"> — </span>Sialic acid-binding immunoglobulin-like lectin (Siglec) 6 and Siglec-8 are expressed on mast cells and eosinophils, and therapeutic targeting of Siglec 8 is under investigation for treatment of diseases of mast cell expansion and activation [<a href="#rid63">63-66</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Leukocyte immunoglobulin-like receptor 4</span><span class="headingEndMark"> — </span>Murine mast cells express LILRB4, an inhibitory receptor with significant homology with the killer cell inhibitory receptors (KIR) found on natural killer (NK) cells [<a href="#rid56">56,67,68</a>]. This molecule was previously called gp49B1. (See  <a class="medical medical_review" href="/d/html/3949.html" rel="external">"NK cell deficiency syndromes: Clinical manifestations and diagnosis"</a>.)</p><p>Mice deficient in LILRB4 have increased severity in local and systemic anaphylaxis, suggesting that this receptor has a "braking function" during mast cell activation [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H12"><span class="h2">CD200 receptor 1</span><span class="headingEndMark"> — </span>The CD200 R1 receptor, a member of the immunoglobulin supergene family that is expressed on myeloid cells, inhibits mast cell degranulation and cytokine secretion [<a href="#rid70">70-72</a>]. It does not contain an ITIM and may play a role in determining the cell's threshold for activation. In contrast, a related member of this family, CD200 R3, has been implicated in mast cell activation [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H627444214"><span class="h2">CD300a</span><span class="headingEndMark"> — </span>CD300a is a type 1 transmembrane protein that contains three classical and one nonclassical ITIM in the intracellular cytoplasmic tail. It is expressed on both myeloid and lymphoid cells. Coligation of the high-affinity IgE receptor and CD300a inhibits mast cell activation [<a href="#rid74">74-77</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Beta-adrenoreceptor 2</span><span class="headingEndMark"> — </span>The beta-adrenoreceptor (beta-2) found on human lung mast cells is linked via a G protein to a cyclic AMP (cAMP) dependent pathway of calcium mobilization [<a href="#rid78">78</a>]. Isolated human lung mast cells display inhibition of degranulation and eicosanoid generation after treatment with beta agonists [<a href="#rid79">79,80</a>].</p><p class="headingAnchor" id="H14"><span class="h2">IgG receptors</span><span class="headingEndMark"> — </span>The IgG receptor Fc-gamma-RIIb is an inhibitory receptor on the surface of mast cells. Fc-gamma-RIIb crosslinking has been shown to reduce IgE-mediated mast cell activation, and investigational therapies based on this mechanism have been reported [<a href="#rid81">81,82</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Toll-like receptor 4</span><span class="headingEndMark"> — </span>Toll-like receptor (TLR) 4 also binds a protein produced by parasitic roundworms, ES-62 [<a href="#rid83">83</a>]. Unlike the binding of TLR4 to lipopolysaccharide (LPS), however, ligation with ES-62 results in inhibition of activation of the cell through Fc-epsilon-RI, and, therefore, TLR4 functions as an inhibitory receptor in this context [<a href="#rid84">84</a>]. Nematodes expressing this protein would be able to modulate the mast cell inflammatory response of the host to infection, thus preventing fulminant inflammation and demise of the host or expulsion of the parasite. Future therapies based upon analogs of ES-62 have been proposed. (See  <a class="medical medical_review" href="/d/html/3985.html" rel="external">"Toll-like receptors: Roles in disease and therapy"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SIGNAL TRANSDUCTION</span><span class="headingEndMark"> — </span>Signal transduction pathways are intertwined webs of molecules through which external information about ongoing events is transmitted to the internal workings of that cell in order to induce a specific effect. These pathways are complex, overlapping, and tightly controlled. The steps in the signal transduction pathway that results from crosslinking of two Fc-epsilon-RI receptors by multivalent antigen on the surface of a mast cell are described here as an example:</p><p class="bulletIndent1"><span class="glyph">●</span>Crosslinking of the Fc-epsilon-RI receptor by polymeric/polyvalent antigens bound to specific IgE at the membrane initiates signal transduction. Specific IgE is bound to the alpha chain of the Fc-epsilon-RI, while the beta and gamma chains are critical for signal transduction. (See <a class="local">'High-affinity IgE receptor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Crosslinking of Fc-epsilon-RI leads to phosphorylation of the <strong>i</strong>mmunoreceptor <strong>t</strong>yrosine-based <strong>a</strong>ctivation <strong>m</strong>otif (ITAM) of the cytoplasmic domain of both the beta and gamma subunits of the receptor complex [<a href="#rid85">85</a>]. The beta chain of Fc-epsilon-RI is constitutively associated with Lyn, a tyrosine kinase belonging to the Src family [<a href="#rid85">85,86</a>]. Tyrosine phosphorylation of the beta subunit activates Lyn [<a href="#rid85">85</a>]. Activated Lyn mediates recruitment of the nonreceptor tyrosine kinase Syk, which interacts via its SH2 domain with the phosphorylated ITAM on the gamma subunit of Fc-epsilon-RI [<a href="#rid85">85,87,88</a>]. Syk then stimulates sequences leading to the mitogen-activated protein kinase (MAPK) pathways and the protein kinase C (PKC) and Ca<sup>2+</sup> dependent pathways [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activation of the MAPK pathway has been linked to the downstream activation of cytosolic phospholipase A2 (cPLA2) in stimulated mast cells [<a href="#rid90">90-93</a>]. The enzyme cPLA2 translocates from a cytosolic to membrane compartment [<a href="#rid94">94</a>], where it cleaves arachidonic acid from phospholipids for the generation of leukotrienes and prostaglandins, as well as forming lyso-phosphatidylcholine, the precursor of platelet-activating factor (PAF).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Syk phosphorylation also causes activation of phosphatidylinositol-specific phospholipase C (PLCg1). The activated PLC cleaves phosphatidylinositol-derived inositol 4,5 bisphosphate (PIP2) to generate the second messengers diacylglycerol (DAG) and inositol 1,4,5 triphosphate (IP3) [<a href="#rid95">95,96</a>]. DAG activates PKC with a consequent translocation to the plasma membrane.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PKC activation results in phosphorylation of numerous proteins including the myosin light chain, which is thought to contribute to exocytosis of mast cell granules and the activation of c-fos and c-jun, leading to enhanced transcription of immediate early genes [<a href="#rid97">97,98</a>]. IP3 acts at the endoplasmic reticulum to release calcium from intracellular stores and activates the calmodulin/calcineurin phosphatase pathway with resultant transcription of cytokine genes, such as interleukin (IL) 6, via the nuclear translocation of the transcription factor nuclear factor of activated T cells (NFAT) [<a href="#rid99">99,100</a>]. Subsequent influx of calcium through the membrane further augments mast cell degranulation [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early activation events lead to the release of granule contents, arachidonic acid metabolites, and tumor necrosis factor (TNF) alpha secretion. Late-phase events include the release of cytokines and chemokines, such as IL-1-beta, IL-6, and newly formed TNF-alpha. (See  <a class="medical medical_review" href="/d/html/3972.html" rel="external">"Mast cell-derived mediators"</a>.)</p><p></p><p class="headingAnchor" id="H174337300"><span class="h1">CLINICAL APPLICATIONS</span><span class="headingEndMark"> — </span>Activating and inhibitory receptors on mast cells and the signaling pathways used by these receptors can be manipulated to achieve specific clinical effects. The following are examples of therapeutic applications that have either already been realized or are in development:</p><p class="bulletIndent1"><span class="glyph">●</span>The high-affinity IgE receptor can be downregulated on the surface of mast cells by administration of the anti-IgE therapy <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>. This agent binds free IgE in the serum and tissues and clears it from circulation, resulting in a reduction in the number of Fc-epsilon-RI receptors present on mast cells (and basophils). Anti-IgE therapy is used in the treatment of allergic asthma. It has also been successfully administered to patients with Hymenoptera venom-induced anaphylaxis who require venom immunotherapy but who have reactions to the injections to improve the safety of the vaccination process. In the future, its use may be extended to other diseases in which IgE is part of the pathophysiology, including allergic rhinitis and anaphylaxis. The use of anti-IgE therapy in asthma and chronic idiopathic urticaria is reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/545.html" rel="external">"Anti-IgE therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The receptor for stem cell factor (SCF), Kit, is a tyrosine kinase. PKC412 (<a class="drug drug_general" data-topicid="112991" href="/d/drug information/112991.html" rel="external">midostaurin</a>) is a tyrosine kinase inhibitor that inhibits Kit, including Kit with a specific D816V mutation, while <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> inhibits only wild-type Kit. Patients with aggressive forms of systemic mastocytosis have benefited from these drugs, providing evidence that activation of Kit is a fundamental part of the pathophysiology of the disease. Patients with severe refractory asthma improve with imatinib, and their lung mast cell numbers decrease [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/d/html/4787.html" rel="external">"Advanced systemic mastocytosis: Management and prognosis", section on 'Midostaurin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Analogs of the parasite product ES-62, an agonist of Toll-like receptor (TLR) 4, are in development. The action of ES-62 at TLR4 leads to inhibition of Fc-epsilon-RI. It is hoped that these agents could be used as immunomodulators to treat or prevent allergic and other inflammatory diseases [<a href="#rid103">103,104</a>]. (See  <a class="medical medical_review" href="/d/html/3985.html" rel="external">"Toll-like receptors: Roles in disease and therapy", section on 'TLR-based therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fusion proteins composed of major allergenic proteins linked to agonists of inhibitory IgG receptors have been developed for the purposes of treating allergic disease. For example, the major cat allergen, Fel d 1, has been fused with Fc-gamma-I and is being studied for use in safer and more effective forms of immunotherapy [<a href="#rid105">105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Syk inhibitors have been studied to block signal transduction in mast cells and prevent activation at the time of allergen exposure, and their application in allergic rhinitis and asthma is under study. However, the potential side effects of blocking signal transduction are complex due to the broad functions of Syk in T cells and other immune cells.</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mast cells have many different stimulatory and inhibitory receptors</strong> – Mast cells display a host of stimulatory and inhibitory surface receptors, and the balance of signals arising from these receptors at a given moment determines the ultimate response of the cell. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Important stimulatory receptors</strong> – Important stimulatory mast cell receptors include the high-affinity immunoglobulin E (IgE) receptor, immunoglobulin G (IgG) receptors, MRGPRX2, Toll-like receptors (TLRs), complement component receptors, and the receptor for stem cell factor (SCF). (See <a class="local">'Activating receptors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Important inhibitory receptors</strong> – Inhibitory receptors act to regulate and modulate mast cell function. Critical inhibitory receptors include leukocyte immunoglobulin-like receptor, subfamily B, member 4 (LILRB4) and CD200R1. (See <a class="local">'Inhibitory receptors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signal transduction</strong> – Signal transduction pathways are complex and precisely controlled networks of molecules, through which information is transmitted from the cell surface to the inside of the cell to induce a specific effect. (See <a class="local">'Signal transduction'</a> above.)</p><p></p><p class="headingAnchor" id="H3197572235"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p><p>The UpToDate editorial staff acknowledges Michael Gurish, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015; 519:237.</a></li><li><a class="nounderline abstract_t">Suzuki R, Leach S, Liu W, et al. Molecular editing of cellular responses by the high-affinity receptor for IgE. Science 2014; 343:1021.</a></li><li><a class="nounderline abstract_t">Uermösi C, Zabel F, Manolova V, et al. IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy 2014; 69:338.</a></li><li><a class="nounderline abstract_t">Havard S, Scola AM, Kay LJ, et al. Characterization of syk expression in human lung mast cells: relationship with function. Clin Exp Allergy 2011; 41:378.</a></li><li><a class="nounderline abstract_t">MacGlashan DW Jr, Schleimer RP, Peters SP, et al. Comparative studies of human basophils and mast cells. Fed Proc 1983; 42:2504.</a></li><li><a class="nounderline abstract_t">Conrad DH, Bazin H, Sehon AH, Froese A. Binding parameters of the interaction between rat IgE and rat mast cell receptors. J Immunol 1975; 114:1688.</a></li><li><a class="nounderline abstract_t">MacGlashan D Jr, McKenzie-White J, Chichester K, et al. In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody. Blood 1998; 91:1633.</a></li><li><a class="nounderline abstract_t">Yamaguchi M, Sayama K, Yano K, et al. IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol 1999; 162:5455.</a></li><li><a class="nounderline abstract_t">Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:E36.</a></li><li><a class="nounderline abstract_t">Kinet JP. The gamma-zeta dimers of Fc receptors as connectors to signal transduction. Curr Opin Immunol 1992; 4:43.</a></li><li><a class="nounderline abstract_t">Cambier JC. Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). J Immunol 1995; 155:3281.</a></li><li><a class="nounderline abstract_t">Ishizaka K, Tomioka H, Ishizaka T. Mechanisms of passive sensitization. I. Presence of IgE and IgG molecules on human leukocytes. J Immunol 1970; 105:1459.</a></li><li><a class="nounderline abstract_t">Kinet JP. The high-affinity receptor for IgE. Curr Opin Immunol 1989- 1990; 2:499.</a></li><li><a class="nounderline abstract_t">Bieber T, de la Salle H, Wollenberg A, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1992; 175:1285.</a></li><li><a class="nounderline abstract_t">Schwartz LB. Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp 2004; 257:65.</a></li><li><a class="nounderline abstract_t">Grayson MH, Cheung D, Rohlfing MM, et al. Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia. J Exp Med 2007; 204:2759.</a></li><li><a class="nounderline abstract_t">McNeil BD. MRGPRX2 and Adverse Drug Reactions. Front Immunol 2021; 12:676354.</a></li><li><a class="nounderline abstract_t">Wedi B, Gehring M, Kapp A. The pseudoallergen receptor MRGPRX2 on peripheral blood basophils and eosinophils: Expression and function. Allergy 2020; 75:2229.</a></li><li><a class="nounderline abstract_t">Meixiong J, Anderson M, Limjunyawong N, et al. Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch. Immunity 2019; 50:1163.</a></li><li><a class="nounderline abstract_t">Serhan N, Basso L, Sibilano R, et al. House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation. Nat Immunol 2019; 20:1435.</a></li><li><a class="nounderline abstract_t">Fujisawa D, Kashiwakura J, Kita H, et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J Allergy Clin Immunol 2014; 134:622.</a></li><li><a class="nounderline abstract_t">Shtessel M, Limjunyawong N, Oliver ET, et al. MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous Urticaria. J Invest Dermatol 2021; 141:678.</a></li><li><a class="nounderline abstract_t">Boyden SE, Desai A, Cruse G, et al. Vibratory Urticaria Associated with a Missense Variant in ADGRE2. N Engl J Med 2016; 374:656.</a></li><li><a class="nounderline abstract_t">Olivera A, Beaven MA, Metcalfe DD. Mast cells signal their importance in health and disease. J Allergy Clin Immunol 2018; 142:381.</a></li><li><a class="nounderline abstract_t">Guo CB, Kagey-Sobotka A, Lichtenstein LM, Bochner BS. Immunophenotyping and functional analysis of purified human uterine mast cells. Blood 1992; 79:708.</a></li><li><a class="nounderline abstract_t">Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: Up-regulation by IFN-gamma. J Immunol 2000; 164:4332.</a></li><li><a class="nounderline abstract_t">Woolhiser MR, Okayama Y, Gilfillan AM, Metcalfe DD. IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. Eur J Immunol 2001; 31:3298.</a></li><li><a class="nounderline abstract_t">Meininger CJ, Yano H, Rottapel R, et al. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 1992; 79:958.</a></li><li><a class="nounderline abstract_t">Murakami M, Austen KF, Arm JP. The immediate phase of c-kit ligand stimulation of mouse bone marrow-derived mast cells elicits rapid leukotriene C4 generation through posttranslational activation of cytosolic phospholipase A2 and 5-lipoxygenase. J Exp Med 1995; 182:197.</a></li><li><a class="nounderline abstract_t">Murakami M, Matsumoto R, Austen KF, Arm JP. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J Biol Chem 1994; 269:22269.</a></li><li><a class="nounderline abstract_t">Lu-Kuo JM, Austen KF, Katz HR. Post-transcriptional stabilization by interleukin-1beta of interleukin-6 mRNA induced by c-kit ligand and interleukin-10 in mouse bone marrow-derived mast cells. J Biol Chem 1996; 271:22169.</a></li><li><a class="nounderline abstract_t">Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 1992; 175:237.</a></li><li><a class="nounderline abstract_t">Costa JJ, Demetri GD, Harrist TJ, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183:2681.</a></li><li><a class="nounderline abstract_t">Feldweg AM, Friend DS, Zhou JS, et al. gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo. Eur J Immunol 2003; 33:2262.</a></li><li><a class="nounderline abstract_t">Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007; 179:2051.</a></li><li><a class="nounderline abstract_t">Gordon ED, Simpson LJ, Rios CL, et al. Alternative splicing of interleukin-33 and type 2 inflammation in asthma. Proc Natl Acad Sci U S A 2016; 113:8765.</a></li><li><a class="nounderline abstract_t">Liu T, Kanaoka Y, Barrett NA, et al. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway. J Immunol 2015; 195:3537.</a></li><li><a class="nounderline abstract_t">Pan D, Buchheit KM, Samuchiwal SK, et al. COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity. J Allergy Clin Immunol 2019; 143:1047.</a></li><li><a class="nounderline abstract_t">Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2016; 137:1566.</a></li><li><a class="nounderline abstract_t">Füreder W, Agis H, Willheim M, et al. Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol 1995; 155:3152.</a></li><li><a class="nounderline abstract_t">el-Lati SG, Dahinden CA, Church MK. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 1994; 102:803.</a></li><li><a class="nounderline abstract_t">Nilsson G, Johnell M, Hammer CH, et al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996; 157:1693.</a></li><li><a class="nounderline abstract_t">Schulman ES, Post TJ, Henson PM, Giclas PC. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 1988; 81:918.</a></li><li><a class="nounderline abstract_t">McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003; 170:1625.</a></li><li><a class="nounderline abstract_t">Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol 2004; 114:174.</a></li><li><a class="nounderline abstract_t">Varadaradjalou S, Féger F, Thieblemont N, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003; 33:899.</a></li><li><a class="nounderline abstract_t">Marshall JS, Jawdat DM. Mast cells in innate immunity. J Allergy Clin Immunol 2004; 114:21.</a></li><li><a class="nounderline abstract_t">Marshall JS, McCurdy JD, Olynych T. Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int Arch Allergy Immunol 2003; 132:87.</a></li><li class="breakAll">Church MK, et al. Functional heterogeneity of human mast cells. In: Mast cell and basophil differentiation and function in health and disease, Galli SJ, Austen KF (Eds), Raven Press, Raven Press 1989.</li><li><a class="nounderline abstract_t">Benyon RC, Lowman MA, Church MK. Human skin mast cells: their dispersion, purification, and secretory characterization. J Immunol 1987; 138:861.</a></li><li><a class="nounderline abstract_t">Church MK, el-Lati S, Caulfield JP. Neuropeptide-induced secretion from human skin mast cells. Int Arch Allergy Appl Immunol 1991; 94:310.</a></li><li><a class="nounderline abstract_t">Aridor M, Traub LM, Sagi-Eisenberg R. Exocytosis in mast cells by basic secretagogues: evidence for direct activation of GTP-binding proteins. J Cell Biol 1990; 111:909.</a></li><li><a class="nounderline abstract_t">Mousli M, Bronner C, Bueb JL, Landry Y. Evidence for the interaction of mast cell-degranulating peptide with pertussis toxin-sensitive G proteins in mast cells. Eur J Pharmacol 1991; 207:249.</a></li><li><a class="nounderline abstract_t">Tatemoto K, Nozaki Y, Tsuda R, et al. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res Commun 2006; 349:1322.</a></li><li><a class="nounderline abstract_t">Gaudenzio N, Sibilano R, Marichal T, et al. Different activation signals induce distinct mast cell degranulation strategies. J Clin Invest 2016; 126:3981.</a></li><li><a class="nounderline abstract_t">Wang LL, Mehta IK, LeBlanc PA, Yokoyama WM. Mouse natural killer cells express gp49B1, a structural homologue of human killer inhibitory receptors. J Immunol 1997; 158:13.</a></li><li><a class="nounderline abstract_t">Stellato C, de Paulis A, Cirillo R, et al. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 1991; 74:1078.</a></li><li><a class="nounderline abstract_t">Moss J, Rosow CE. Histamine release by narcotics and muscle relaxants in humans. Anesthesiology 1983; 59:330.</a></li><li><a class="nounderline abstract_t">Kajiwara N, Sasaki T, Bradding P, et al. Activation of human mast cells through the platelet-activating factor receptor. J Allergy Clin Immunol 2010; 125:1137.</a></li><li><a class="nounderline abstract_t">Katz HR. Inhibitory receptors and allergy. Curr Opin Immunol 2002; 14:698.</a></li><li><a class="nounderline abstract_t">Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007; 120:506.</a></li><li><a class="nounderline abstract_t">Yokoi H, Myers A, Matsumoto K, et al. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells. Allergy 2006; 61:769.</a></li><li><a class="nounderline abstract_t">Duan S, Paulson JC. Siglecs as Immune Cell Checkpoints in Disease. Annu Rev Immunol 2020; 38:365.</a></li><li><a class="nounderline abstract_t">O'Sullivan JA, Chang AT, Youngblood BA, Bochner BS. Eosinophil and mast cell Siglecs: From biology to drug target. J Leukoc Biol 2020; 108:73.</a></li><li><a class="nounderline abstract_t">Dellon ES, Peterson KA, Murray JA, et al. Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. N Engl J Med 2020; 383:1624.</a></li><li><a class="nounderline abstract_t">Youngblood BA, Leung J, Falahati R, et al. Discovery, Function, and Therapeutic Targeting of Siglec-8. Cells 2020; 10.</a></li><li><a class="nounderline abstract_t">Daëron M, Malbec O, Latour S, et al. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995; 95:577.</a></li><li><a class="nounderline abstract_t">Daheshia M, Friend DS, Grusby MJ, et al. Increased severity of local and systemic anaphylactic reactions in gp49B1-deficient mice. J Exp Med 2001; 194:227.</a></li><li><a class="nounderline abstract_t">Zhou JS, Friend DS, Lee DM, et al. gp49B1 deficiency is associated with increases in cytokine and chemokine production and severity of proliferative synovitis induced by anti-type II collagen mAb. Eur J Immunol 2005; 35:1530.</a></li><li><a class="nounderline abstract_t">Voehringer D, Rosen DB, Lanier LL, Locksley RM. CD200 receptor family members represent novel DAP12-associated activating receptors on basophils and mast cells. J Biol Chem 2004; 279:54117.</a></li><li><a class="nounderline abstract_t">Cherwinski HM, Murphy CA, Joyce BL, et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 2005; 174:1348.</a></li><li><a class="nounderline abstract_t">Zhang S, Phillips JH. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukoc Biol 2006; 79:363.</a></li><li><a class="nounderline abstract_t">Kojima T, Obata K, Mukai K, et al. Mast cells and basophils are selectively activated in vitro and in vivo through CD200R3 in an IgE-independent manner. J Immunol 2007; 179:7093.</a></li><li><a class="nounderline abstract_t">Bachelet I, Munitz A, Moretta A, et al. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol 2005; 175:7989.</a></li><li><a class="nounderline abstract_t">Okoshi Y, Tahara-Hanaoka S, Nakahashi C, et al. Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3. Int Immunol 2005; 17:65.</a></li><li><a class="nounderline abstract_t">Simhadri VR, Andersen JF, Calvo E, et al. Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 2012; 119:2799.</a></li><li><a class="nounderline abstract_t">Nakahashi-Oda C, Tahara-Hanaoka S, Shoji M, et al. Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor. J Exp Med 2012; 209:1493.</a></li><li><a class="nounderline abstract_t">Chong LK, Morice AH, Yeo WW, et al. Functional desensitization of beta agonist responses in human lung mast cells. Am J Respir Cell Mol Biol 1995; 13:540.</a></li><li><a class="nounderline abstract_t">Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 1987; 90:421.</a></li><li><a class="nounderline abstract_t">Okayama Y, Church MK. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int Arch Allergy Immunol 1992; 97:216.</a></li><li><a class="nounderline abstract_t">Zhu D, Kepley CL, Zhang K, et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11:446.</a></li><li><a class="nounderline abstract_t">Mertsching E, Bafetti L, Hess H, et al. A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases. J Allergy Clin Immunol 2008; 121:441.</a></li><li><a class="nounderline abstract_t">Goodridge HS, Marshall FA, Else KJ, et al. Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62. J Immunol 2005; 174:284.</a></li><li><a class="nounderline abstract_t">Melendez AJ, Harnett MM, Pushparaj PN, et al. Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes. Nat Med 2007; 13:1375.</a></li><li><a class="nounderline abstract_t">Jouvin MH, Adamczewski M, Numerof R, et al. Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J Biol Chem 1994; 269:5918.</a></li><li><a class="nounderline abstract_t">Yamashita T, Mao SY, Metzger H. Aggregation of the high-affinity IgE receptor and enhanced activity of p53/56lyn protein-tyrosine kinase. Proc Natl Acad Sci U S A 1994; 91:11251.</a></li><li><a class="nounderline abstract_t">Wilson BS, Kapp N, Lee RJ, et al. Distinct functions of the Fc epsilon R1 gamma and beta subunits in the control of Fc epsilon R1-mediated tyrosine kinase activation and signaling responses in RBL-2H3 mast cells. J Biol Chem 1995; 270:4013.</a></li><li><a class="nounderline abstract_t">Oliver JM, Burg DL, Wilson BS, et al. Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem 1994; 269:29697.</a></li><li><a class="nounderline abstract_t">Kambayashi T, Koretzky GA. Proximal signaling events in Fc epsilon RI-mediated mast cell activation. J Allergy Clin Immunol 2007; 119:544.</a></li><li><a class="nounderline abstract_t">Blumer KJ, Johnson GL. Diversity in function and regulation of MAP kinase pathways. Trends Biochem Sci 1994; 19:236.</a></li><li><a class="nounderline abstract_t">Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995; 20:117.</a></li><li><a class="nounderline abstract_t">Hirasawa N, Santini F, Beaven MA. Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different pathways for release of arachidonic acid and secretory granules. J Immunol 1995; 154:5391.</a></li><li><a class="nounderline abstract_t">Hirasawa N, Scharenberg A, Yamamura H, et al. A requirement for Syk in the activation of the microtubule-associated protein kinase/phospholipase A2 pathway by Fc epsilon R1 is not shared by a G protein-coupled receptor. J Biol Chem 1995; 270:10960.</a></li><li><a class="nounderline abstract_t">Glover S, de Carvalho MS, Bayburt T, et al. Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J Biol Chem 1995; 270:15359.</a></li><li><a class="nounderline abstract_t">Divecha N, Irvine RF. Phospholipid signaling. Cell 1995; 80:269.</a></li><li><a class="nounderline abstract_t">Fukamachi H, Kawakami Y, Takei M, et al. Association of protein-tyrosine kinase with phospholipase C-gamma 1 in bone marrow-derived mouse mast cells. Proc Natl Acad Sci U S A 1992; 89:9524.</a></li><li><a class="nounderline abstract_t">Lewin I, Jacob-Hirsch J, Zang ZC, et al. Aggregation of the Fc epsilon RI in mast cells induces the synthesis of Fos-interacting protein and increases its DNA binding-activity: the dependence on protein kinase C-beta. J Biol Chem 1996; 271:1514.</a></li><li><a class="nounderline abstract_t">Razin E, Szallasi Z, Kazanietz MG, et al. Protein kinases C-beta and C-epsilon link the mast cell high-affinity receptor for IgE to the expression of c-fos and c-jun. Proc Natl Acad Sci U S A 1994; 91:7722.</a></li><li><a class="nounderline abstract_t">Marquardt DL, Alongi JL, Walker LL. The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. J Immunol 1996; 156:1942.</a></li><li><a class="nounderline abstract_t">Fruman DA, Bierer BE, Benes JE, et al. The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol 1995; 154:1846.</a></li><li><a class="nounderline abstract_t">Penner R, Matthews G, Neher E. Regulation of calcium influx by second messengers in rat mast cells. Nature 1988; 334:499.</a></li><li><a class="nounderline abstract_t">Cahill KN, Katz HR, Cui J, et al. KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. N Engl J Med 2017; 376:1911.</a></li><li><a class="nounderline abstract_t">Erb KJ. Can helminths or helminth-derived products be used in humans to prevent or treat allergic diseases? Trends Immunol 2009; 30:75.</a></li><li><a class="nounderline abstract_t">Harnett MM, Melendez AJ, Harnett W. The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease. Clin Exp Immunol 2010; 159:256.</a></li><li><a class="nounderline abstract_t">Zhang K, Zhu D, Kepley C, et al. Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy. Immunol Allergy Clin North Am 2007; 27:93.</a></li></ol></div><div id="topicVersionRevision">Topic 3981 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25517090" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24505132" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular editing of cellular responses by the high-affinity receptor for IgE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24354793" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21255137" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Characterization of syk expression in human lung mast cells: relationship with function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6301890" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparative studies of human basophils and mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/805173" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Binding parameters of the interaction between rat IgE and rat mast cell receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9473229" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228025" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11483846" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1534484" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The gamma-zeta dimers of Fc receptors as connectors to signal transduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7561018" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4098503" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mechanisms of passive sensitization. I. Presence of IgE and IgG molecules on human leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The high-affinity receptor for IgE</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1533242" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15025392" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effector cells of anaphylaxis: mast cells and basophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954569" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34421893" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : MRGPRX2 and Adverse Drug Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32003863" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The pseudoallergen receptor MRGPRX2 on peripheral blood basophils and eosinophils: Expression and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31027996" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31591569" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24954276" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32771471" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous Urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26841242" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Vibratory Urticaria Associated with a Missense Variant in ADGRE2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29454835" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mast cells signal their importance in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1370642" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Immunophenotyping and functional analysis of purified human uterine mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10754333" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: Up-regulation by IFN-gamma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745347" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1371080" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The c-kit receptor ligand functions as a mast cell chemoattractant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7540649" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The immediate phase of c-kit ligand stimulation of mouse bone marrow-derived mast cells elicits rapid leukotriene C4 generation through posttranslational activation of cytosolic phospholipase A2 and 5-lipoxygenase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8071353" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8703029" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Post-transcriptional stabilization by interleukin-1beta of interleukin-6 mRNA induced by c-kit ligand and interleukin-10 in mouse bone marrow-derived mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1370529" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : c-kit ligand: a unique potentiator of mediator release by human lung mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8676090" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12884301" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17675461" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27432971" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Alternative splicing of interleukin-33 and type 2 inflammation in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342029" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30017554" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26691435" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7673728" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7513741" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759757" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2449462" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12574323" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15241362" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672055" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15241339" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mast cells in innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14600420" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Toll-like receptor-mediated activation of mast cells: implications for allergic disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14600420" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Toll-like receptor-mediated activation of mast cells: implications for allergic disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2433332" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Human skin mast cells: their dispersion, purification, and secretory characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718893" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Neuropeptide-induced secretion from human skin mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1697300" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Exocytosis in mast cells by basic secretagogues: evidence for direct activation of GTP-binding proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1716580" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Evidence for the interaction of mast cell-degranulating peptide with pertussis toxin-sensitive G proteins in mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979137" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27643442" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Different activation signals induce distinct mast cell degranulation strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8977170" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mouse natural killer cells express gp49B1, a structural homologue of human killer inhibitory receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1710428" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Heterogeneity of human mast cells and basophils in response to muscle relaxants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6193743" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Histamine release by narcotics and muscle relaxants in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20392487" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Activation of human mast cells through the platelet-activating factor receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12413518" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Inhibitory receptors and allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765751" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Anaphylaxis: lessons from mouse models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677248" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31986070" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Siglecs as Immune Cell Checkpoints in Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31965606" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Eosinophil and mast cell Siglecs: From biology to drug target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33085861" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33374255" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Discovery, Function, and Therapeutic Targeting of Siglec-8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7860741" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11457897" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Increased severity of local and systemic anaphylactic reactions in gp49B1-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827966" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : gp49B1 deficiency is associated with increases in cytokine and chemokine production and severity of proliferative synovitis induced by anti-type II collagen mAb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15471863" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : CD200 receptor family members represent novel DAP12-associated activating receptors on basophils and mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15661892" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The CD200 receptor is a novel and potent regulator of murine and human mast cell function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330532" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17982101" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mast cells and basophils are selectively activated in vitro and in vivo through CD200R3 in an IgE-independent manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16339535" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569773" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22302738" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22826299" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7576689" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Functional desensitization of beta agonist responses in human lung mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2435353" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1375203" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793580" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A chimeric human-cat fusion protein blocks cat-induced allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17949802" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15611251" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17952092" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8119935" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7526394" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Aggregation of the high-affinity IgE receptor and enhanced activity of p53/56lyn protein-tyrosine kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7876149" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Distinct functions of the Fc epsilon R1 gamma and beta subunits in the control of Fc epsilon R1-mediated tyrosine kinase activation and signaling responses in RBL-2H3 mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7961959" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336609" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Proximal signaling events in Fc epsilon RI-mediated mast cell activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8073500" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Diversity in function and regulation of MAP kinase pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7709430" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Parallel signal processing among mammalian MAPKs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7730640" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different pathways for release of arachidonic acid and secretory granules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7537741" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A requirement for Syk in the activation of the microtubule-associated protein kinase/phospholipase A2 pathway by Fc epsilon R1 is not shared by a G protein-coupled receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797525" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7834746" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Phospholipid signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1384056" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Association of protein-tyrosine kinase with phospholipase C-gamma 1 in bone marrow-derived mouse mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8576146" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Aggregation of the Fc epsilon RI in mast cells induces the synthesis of Fos-interacting protein and increases its DNA binding-activity: the dependence on protein kinase C-beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8052650" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Protein kinases C-beta and C-epsilon link the mast cell high-affinity receptor for IgE to the expression of c-fos and c-jun.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596048" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7530743" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2457169" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Regulation of calcium influx by second messengers in rat mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28514613" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138565" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Can helminths or helminth-derived products be used in humans to prevent or treat allergic diseases?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19968663" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276881" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
